Gastric Cancer: Pathology Grant N. Stemmermann Cecilia M. Fenoglio-Preiser Gastric cancers represent a heterogeneous group of tumors, most lesions being adenocarcinomas. The less common gastric cancers, such as lymphomas, neuroendocrine…
Gastric Cancer: Staging Systems and Techniques Mark Greaves Arnold Markowitz Hans Gerdes In the early 1900s, it was observed that survival rates for cancer were higher for patients in whom…
Gastric Cancer: Molecular Biology and Genetics Rajnish Mishra Steven M. Powell Introduction General Epidemiology Gastric carcinoma remains one of the world’s most common cancers and a leading cause of cancer…
Gastric Cancer: Epidemiology, Screening, Surveillance, and Prevention Rene Lambert Donald M. Parkin Incidence Survival and Mortality from Gastric Cancer Despite a declining incidence, stomach cancer is still one of the…
Esophageal Cancer: Clinical Management J. Rüdiger Siewert Michael Molls Frank Zimmermann Florian Lordick In contrast to gastric cancer incidence, which is decreasing worldwide, the incidence and prevalence of esophageal carcinoma…
Esophageal Cancer: Anatomy and Staging Richard P.M. Koehler Frank C. Detterbeck David A. Dean The surgical treatment of esophageal cancer requires today’s surgeons to not only have a thorough knowledge…
Esophageal Cancer: Pathology Susan C. Abraham Tsung-Teh Wu Esophageal cancer is an aggressive disease with a poor prognosis. In 2005, it is estimated that there will be approximately 14,000 new…
The Molecular Genetics of Esophageal Cancer James P. Hamilton Stephen J. Meltzer Introduction Esophageal cancer (EC) is the eighth most common malignancy and the sixth most common cause of cancer…
Esophageal Cancer: Epidemiology, Screening, and Prevention Evan S. Dellon Nicholas J. Shaheen Esophageal malignancies are relatively uncommon in the United States, and because they are often diagnosed at an advanced…
Pain and Symptom Control Russell K. Portenoy Craig D. Blinderman Introduction Approximately 30% to 50% of cancer patients undergoing antineoplastic therapy and 75% to 90% of patients with advanced disease…
